Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0000567
UniProt IDP24941
Primary gene name(s)CDK2
Synonym gene name(s)CDKN2
Protein nameCyclin-dependent kinase 2
Protein functionSerine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2. Interacts with cyclins A, B1, B3, D, or E. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression; controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus. Crucial role in orchestrating a fine balance between cellular proliferation, cell death, and DNA repair in human embryonic stem cells, hESCs. Activity of CDK2 is maximal during S phase and G2; activated by interaction with cyclin E during the early stages of DNA synthesis to permit G1-S transition, and subsequently activated by cyclin A2, cyclin A1 in germ cells during the late stages of DNA replication to drive the transition from S phase to mitosis, the G2 phase. EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing. Phosphorylates CABLES1, By similarity. Cyclin E/CDK2 prevents oxidative stress-mediated Ras-induced senescence by phosphorylating MYC. Involved in G1-S phase DNA damage checkpoint that prevents cells with damaged DNA from initiating mitosis; regulates homologous recombination-dependent repair by phosphorylating BRCA2, this phosphorylation is low in S phase when recombination is active, but increases as cells progress towards mitosis. In response to DNA damage, double-strand break repair by homologous recombination a reduction of CDK2-mediated BRCA2 phosphorylation. Phosphorylation of RB1 disturbs its interaction with E2F1. NPM1 phosphorylation by cyclin E/CDK2 promotes its dissociates from unduplicated centrosomes, thus initiating centrosome duplication. Cyclin E/CDK2-mediated phosphorylation of NPAT at G1-S transition and until prophase stimulates the NPAT-mediated activation of histone gene transcription during S phase. Required for vitamin D-mediated growth inhibition by being itself inactivated. Involved in the nitric oxide-, NO mediated signaling in a nitrosylation/activation-dependent manner. USP37 is activated by phosphorylation and thus triggers G1-S transition. CTNNB1 phosphorylation regulates insulin internalization. Phosphorylates FOXP3 and negatively regulates its transcriptional activity and protein stability, By similarity. {ECO:0000250|UniProtKB:P97377, ECO:0000269|PubMed:10499802, ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:10995386, ECO:0000269|PubMed:10995387, ECO:0000269|PubMed:11051553, ECO:0000269|PubMed:11113184, ECO:0000269|PubMed:15800615, ECO:0000269|PubMed:17495531, ECO:0000269|PubMed:18372919, ECO:0000269|PubMed:19966300, ECO:0000269|PubMed:20079829, ECO:0000269|PubMed:20147522, ECO:0000269|PubMed:20195506, ECO:0000269|PubMed:20935635, ECO:0000269|PubMed:21262353, ECO:0000269|PubMed:21319273, ECO:0000269|PubMed:21596315}.
Subcellular locationCytoplasm, cytoskeleton, microtubule organizing center, centrosome. Nucleus, Cajal body. Cytoplasm. Endosome. Note=Localized at the centrosomes in late G2 phase after separation of the centrosomes but before the start of prophase. Nuclear-cytoplasmic trafficking is mediated during the inhibition by 1,25-(OH(2D(3.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P24941
Gene Ontology
(Biological Process)
Complete annatation
cell division [GO:0051301];
cellular response to nitric oxide [GO:0071732];
centriole replication [GO:0007099];
centrosome duplication [GO:0051298];
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest [GO:0006977];
DNA repair [GO:0006281];
DNA replication [GO:0006260];
G1/S transition of mitotic cell cycle [GO:0000082];
G2/M transition of mitotic cell cycle [GO:0000086];
histone phosphorylation [GO:0016572];
meiotic nuclear division [GO:0007126];
mitotic G1 DNA damage checkpoint [GO:0031571];
mitotic nuclear division [GO:0007067];
negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle [GO:0051436];
peptidyl-serine phosphorylation [GO:0018105];
positive regulation of cell proliferation [GO:0008284];
positive regulation of DNA-dependent DNA replication initiation [GO:0032298];
positive regulation of transcription, DNA-templated [GO:0045893];
potassium ion transport [GO:0006813];
Ras protein signal transduction [GO:0007265];
regulation of gene silencing [GO:0060968];
regulation of signal transduction by p53 class mediator [GO:1901796];
regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle [GO:0051439]
Gene Ontology
(Molecular Function)
Complete annatation
ATP binding [GO:0005524];
cyclin binding [GO:0030332];
cyclin-dependent protein serine/threonine kinase activity [GO:0004693];
kinase activity [GO:0016301];
metal ion binding [GO:0046872];
protein serine/threonine kinase activity [GO:0004674]
Gene Ontology
(Cellular Component)
Complete annatation
Cajal body [GO:0015030];
centrosome [GO:0005813];
chromosome, telomeric region [GO:0000781];
condensed chromosome [GO:0000793];
cyclin-dependent protein kinase holoenzyme complex [GO:0000307];
cytoplasm [GO:0005737];
cytosol [GO:0005829];
endosome [GO:0005768];
nucleoplasm [GO:0005654];
nucleus [GO:0005634];
transcription factor complex [GO:0005667];
X chromosome [GO:0000805];
Y chromosome [GO:0000806]
Protein-protein interaction107452
Phylogenetic treeP24941
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD31.266410155575870.0834902049035890.15179304804667
AZA vs. DISU0.2614803541563410.3066111801721680.865456570028109
AZA vs. IL70.391129431251540.04591325289784610.638415914185047
AZA vs. SAHA1.129797302358140.0004109719423087690.0112228098883376
DISU vs. CD3-1.018207783185430.1560919212686210.263966036369907
DISU vs. IL70.1202673785794320.6349744626898840.891519048621589
DISU vs. SAHA0.8708922517011410.01272146639167950.121115110542641
DMSO vs. AZA0.01793799519385630.9166414080834741
DMSO vs. CD3-1.259617610220560.08496855543676960.149573648943087
DMSO vs. DISU-0.2452569016898260.3198632515350510.822115156577384
DMSO vs. IL70.3801878040169670.03800079638887990.400168947736717
DMSO vs. SAHA1.106130142166010.000489653131505730.0105967256325625
HIV vs. Mock in Activation0.1694098852531460.9084262890732330.999983755607037
HIV vs. Mock in Latency-0.09320202238793750.5805571775152920.999834320637052
IL7 vs. CD3-0.8689630429993490.2283948062272960.357004554004359
SAHA vs. CD3-0.1607075783076790.8531755329867940.895920513003343
SAHA vs. IL70.7369022120712280.04135402674080380.160880197467571
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change -0.966587725
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.435653 0.000305467
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.999 1.138 1.27 1.17 1.166
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB01888 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide experimental unknown unknown
DB02010 Staurosporine experimental unknown unknown
DB02091 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine experimental unknown unknown
DB02116 Olomoucine experimental unknown inhibitor
DB02197 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide experimental unknown unknown
DB02297 2-Amino-6-Chloropyrazine experimental unknown unknown
DB02407 6-O-Cyclohexylmethyl Guanine experimental unknown unknown
DB02538 N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide experimental unknown unknown
DB02603 1-Amino-6-Cyclohex-3-Enylmethyloxypurine experimental unknown unknown
DB02647 N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide experimental unknown unknown
DB02733 Purvalanol experimental unknown unknown
DB02833 [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine experimental unknown unknown
DB02898 5-{[(2-Amino-9h-Purin-6-Yl)Oxy]Methyl}-2-Pyrrolidinone experimental unknown unknown
DB02915 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(4-Trifluoromethyl-Phenyl)-Amine experimental unknown unknown
DB02950 Hymenialdisine experimental unknown inhibitor
DB02963 (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine experimental unknown unknown
DB02973 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide experimental unknown unknown
DB03019 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine experimental unknown unknown
DB03307 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide experimental unknown unknown
DB03365 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline experimental unknown unknown
DB03428 SU9516 experimental unknown inhibitor
DB03490 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole experimental unknown unknown
DB03583 (2e,3s)-3-Hydroxy-5&,39;-[(4-Hydroxypiperidin-1-Yl)Sulfonyl]-3-Methyl-1,3-Dihydro-2,3&,39;-Biindol-2&,39;(1&,39;h)-One experimental unknown unknown
DB03663 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol experimental unknown unknown
DB03737 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One experimental unknown unknown
DB03801 Lysine Nz-Carboxylic Acid experimental unknown unknown
DB04006 [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone experimental unknown unknown
DB04101 N-[4-(2,4-Dimethyl-1,3-Thiazol-5-Yl)Pyrimidin-2-Yl]-N&,39;-Hydroxyimidoformamide experimental unknown unknown
DB04186 N&,39;-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea experimental unknown unknown
DB04288 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine experimental unknown unknown
DB04407 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol experimental unknown unknown
DB04518 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol experimental unknown unknown
DB05037 AT7519 investigational unknown unknown
DB04607 PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE experimental unknown unknown
DB04662 OLOMOUCINE II experimental unknown unknown
DB04669 TRIAZOLOPYRIMIDINE experimental unknown unknown
DB03496 Flavopiridol experimental, investigational unknown inhibitor
DB06844 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE experimental unknown unknown
DB06888 (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE experimental unknown unknown
DB06944 N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide experimental unknown unknown
DB06948 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE experimental unknown unknown
DB06976 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA experimental unknown unknown
DB06983 (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol experimental unknown unknown
DB07024 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE experimental unknown unknown
DB07065 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine experimental unknown unknown
DB07126 O6-CYCLOHEXYLMETHOXY-2-(4&,39;-SULPHAMOYLANILINO) PURINE experimental unknown unknown
DB07137 (2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDE experimental unknown unknown
DB07163 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE experimental unknown unknown
DB07164 N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine experimental unknown unknown
DB07179 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide experimental unknown unknown
DB07203 6-CYCLOHEXYLMETHOXY-2-(3&,39;-CHLOROANILINO) PURINE experimental unknown unknown
DB07210 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine experimental unknown unknown
DB07220 N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE experimental unknown unknown
DB07431 (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one experimental unknown unknown
DB07493 (2Z)-5&,39;-BROMO-2,3&,39;-BIINDOLE-2&,39;,3(1H,1&,39;H)-DIONE AMMONIATE experimental unknown unknown
DB07501 (2S)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL experimental unknown unknown
DB07504 (2R)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL experimental unknown unknown
DB07529 2-IMINO-5-(1-PYRIDIN-2-YL-METH-(E)-YLIDENE)-1,3-THIAZOLIDIN-4-ONE experimental unknown unknown
DB07531 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE experimental unknown unknown
DB07533 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE experimental unknown unknown
DB07534 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE experimental unknown unknown
DB07539 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID experimental unknown unknown
DB07540 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE experimental unknown unknown
DB07562 N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N&,39;,N&,39;-DIMETHYL-BENZENE-1,4-DIAMINE experimental unknown unknown
DB07595 (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE experimental unknown unknown
DB07606 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE experimental unknown unknown
DB07612 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE experimental unknown unknown
DB07622 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA experimental unknown unknown
DB07686 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE experimental unknown unknown
DB07687 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE experimental unknown unknown
DB07688 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE experimental unknown unknown
DB07731 4-[(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYL]PHENOL experimental unknown unknown
DB07750 (2R)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL experimental unknown unknown
DB07751 (2S)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL experimental unknown unknown
DB07755 (2S)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL experimental unknown unknown
DB07761 (2R)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL experimental unknown unknown
DB07852 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID experimental unknown unknown
DB07889 1-(DIMETHYLAMINO)-3-(4-{{4-(2-METHYLIMIDAZO[1,2-A]PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO}PHENOXY)PROPAN-2-OL experimental unknown unknown
DB07936 N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine experimental unknown unknown
DB07982 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol experimental unknown unknown
DB02052 Indirubin-3&,39;-Monoxime experimental unknown inhibitor
DB08066 N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE experimental unknown unknown
DB08124 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE experimental unknown unknown
DB08125 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE experimental unknown unknown
DB08132 5-hydroxynaphthalene-1-sulfonamide experimental unknown unknown
DB08133 N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide experimental unknown unknown
DB08134 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide experimental unknown unknown
DB08135 N-phenyl-1H-pyrazole-3-carboxamide experimental unknown unknown
DB08136 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide experimental unknown unknown
DB08137 (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide experimental unknown unknown
DB08138 {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide experimental unknown unknown
DB08139 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile experimental unknown unknown
DB08141 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide experimental unknown unknown
DB08142 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide experimental unknown unknown
DB08178 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine experimental unknown unknown
DB08182 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine experimental unknown unknown
DB08218 HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM experimental unknown unknown
DB08219 4-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE experimental unknown unknown
DB08233 6-CYCLOHEXYLMETHYLOXY-2-(4&,39;-HYDROXYANILINO)PURINE experimental unknown unknown
DB08241 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE experimental unknown unknown
DB08247 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE experimental unknown unknown
DB08285 (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol experimental unknown unknown
DB08309 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL experimental unknown unknown
DB08312 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE experimental unknown unknown
DB08355 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid experimental unknown unknown
DB08441 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE experimental unknown unknown
DB08463 (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol experimental unknown unknown
DB08527 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE experimental unknown unknown
DB08531 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine experimental unknown unknown
DB08532 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine experimental unknown unknown
DB08533 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine experimental unknown unknown
DB08534 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine experimental unknown unknown
DB08535 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine experimental unknown unknown
DB08536 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine experimental unknown unknown
DB08537 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine experimental unknown unknown
DB08538 N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine experimental unknown unknown
DB08539 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine experimental unknown unknown
DB08673 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE experimental unknown unknown
DB08677 N-(5-ISOPROPYL-THIAZOL-2-YL)-2-PYRIDIN-3-YL-ACETAMIDE experimental unknown unknown
DB08694 9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3&,39;,2&,39;:4,5]pyrrolo[1,2-c]pyrimidin-4-ol experimental unknown unknown
DB08768 N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE experimental unknown unknown
DB06616 Bosutinib approved unknown inhibitor

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1AQ1 X-ray 2.0Å A=1-298.
1B38 X-ray 2.0Å A=1-298.
1B39 X-ray 2.1Å A=1-298.
1BUH X-ray 2.6Å A=1-298.
1CKP X-ray 2.0Å A=1-298.
1DI8 X-ray 2.2Å A=1-298.
1DM2 X-ray 2.1Å A=1-298.
1E1V X-ray 1.9Å A=1-298.
1E1X X-ray 1.8Å A=1-298.
1E9H X-ray 2.5Å A/C=1-296.
1F5Q X-ray 2.5Å A/C=1-298.
1FIN X-ray 2.3Å A/C=1-298.
1FQ1 X-ray 3.0Å B=1-298.
1FVT X-ray 2.2Å A=1-298.
1FVV X-ray 2.8Å A/C=1-298.
1G5S X-ray 2.6Å A=1-298.
1GIH X-ray 2.8Å A=1-298.
1GII X-ray 2.0Å A=1-298.
1GIJ X-ray 2.2Å A=1-298.
1GY3 X-ray 2.7Å A/C=1-296.
1GZ8 X-ray 1.3Å A=1-298.
1H00 X-ray 1.6Å A=1-298.
1H01 X-ray 1.7Å A=1-298.
1H07 X-ray 1.8Å A=1-298.
1H08 X-ray 1.8Å A=1-298.
1H0V X-ray 1.9Å A=1-298.
1H0W X-ray 2.1Å A=1-298.
1H1P X-ray 2.1Å A/C=1-298.
1H1Q X-ray 2.5Å A/C=1-298.
1H1R X-ray 2.0Å A/C=1-298.
1H1S X-ray 2.0Å A/C=1-298.
1H24 X-ray 2.5Å A/C=1-298.
1H25 X-ray 2.5Å A/C=1-298.
1H26 X-ray 2.2Å A/C=1-298.
1H27 X-ray 2.2Å A/C=1-298.
1H28 X-ray 2.8Å A/C=1-298.
1HCK X-ray 1.9Å A=1-298.
1HCL X-ray 1.8Å A=1-298.
1JST X-ray 2.6Å A/C=1-298.
1JSU X-ray 2.3Å A=1-298.
1JSV X-ray 1.9Å A=1-298.
1JVP X-ray 1.5Å P=1-298.
1KE5 X-ray 2.2Å A=1-298.
1KE6 X-ray 2.0Å A=1-298.
1KE7 X-ray 2.0Å A=1-298.
1KE8 X-ray 2.0Å A=1-298.
1KE9 X-ray 2.0Å A=1-298.
1OGU X-ray 2.6Å A/C=1-298.
1OI9 X-ray 2.1Å A/C=1-298.
1OIQ X-ray 2.3Å A=1-298.
1OIR X-ray 1.9Å A=1-298.
1OIT X-ray 1.6Å A=1-298.
1OIU X-ray 2.0Å A/C=1-298.
1OIY X-ray 2.4Å A/C=1-298.
1OKV X-ray 2.4Å A/C=1-298.
1OKW X-ray 2.5Å A/C=1-298.
1OL1 X-ray 2.9Å A/C=1-298.
1OL2 X-ray 2.6Å A/C=1-298.
1P2A X-ray 2.5Å A=1-298.
1P5E X-ray 2.2Å A/C=1-298.
1PF8 X-ray 2.5Å A=1-298.
1PKD X-ray 2.3Å A/C=1-296.
1PW2 X-ray 1.9Å A=1-298.
1PXI X-ray 1.9Å A=1-298.
1PXJ X-ray 2.3Å A=1-298.
1PXK X-ray 2.8Å A=1-298.
1PXL X-ray 2.5Å A=1-298.
1PXM X-ray 2.5Å A=1-298.
1PXN X-ray 2.5Å A=1-298.
1PXO X-ray 1.9Å A=1-298.
1PXP X-ray 2.3Å A=1-298.
1PYE X-ray 2.0Å A=1-298.
1QMZ X-ray 2.2Å A/C=1-298.
1R78 X-ray 2.0Å A=1-298.
1URC X-ray 2.6Å A/C=1-298.
1URW X-ray 1.6Å A=1-298.
1V1K X-ray 2.3Å A=1-298.
1VYW X-ray 2.3Å A/C=1-298.
1VYZ X-ray 2.2Å A=1-298.
1W0X X-ray 2.2Å C=1-298.
1W8C X-ray 2.0Å A=1-298.
1W98 X-ray 2.1Å A=1-297.
1WCC X-ray 2.2Å A=1-298.
1Y8Y X-ray 2.0Å A=1-298.
1Y91 X-ray 2.1Å A=1-298.
1YKR X-ray 1.8Å A=1-298.
2A0C X-ray 1.9Å X=1-298.
2A4L X-ray 2.4Å A=1-298.
2B52 X-ray 1.8Å A=1-298.
2B53 X-ray 2.0Å A=1-298.
2B54 X-ray 1.8Å A=1-298.
2B55 X-ray 1.8Å A=1-298.
2BHE X-ray 1.9Å A=1-298.
2BHH X-ray 2.6Å A=1-298.
2BKZ X-ray 2.6Å A/C=1-298.
2BPM X-ray 2.4Å A/C=1-298.
2BTR X-ray 1.8Å A=1-298.
2BTS X-ray 1.9Å A=1-298.
2C4G X-ray 2.7Å A/C=1-298.
2C5N X-ray 2.1Å A/C=1-298.
2C5O X-ray 2.1Å A/C=1-298.
2C5V X-ray 2.9Å A/C=1-298.
2C5X X-ray 2.9Å A/C=1-298.
2C5Y X-ray 2.2Å A=1-298.
2C68 X-ray 1.9Å A=1-298.
2C69 X-ray 2.1Å A=1-298.
2C6I X-ray 1.8Å A=1-298.
2C6K X-ray 1.9Å A=1-298.
2C6L X-ray 2.3Å A=1-298.
2C6M X-ray 1.9Å A=1-298.
2C6O X-ray 2.1Å A=1-298.
2C6T X-ray 2.6Å A/C=1-298.
2CCH X-ray 1.7Å A/C=1-298.
2CCI X-ray 2.7Å A/C=1-298.
2CJM X-ray 2.3Å A/C=1-298.
2CLX X-ray 1.8Å A=1-298.
2DS1 X-ray 2.0Å A=1-298.
2DUV X-ray 2.2Å A=1-298.
2EXM X-ray 1.8Å A=1-298.
2FVD X-ray 1.8Å A=1-298.
2G9X X-ray 2.5Å A/C=1-298.
2HIC Model - A=1-298.
2I40 X-ray 2.8Å A/C=1-298.
2IW6 X-ray 2.3Å A/C=1-298.
2IW8 X-ray 2.3Å A/C=1-298.
2IW9 X-ray 2.0Å A/C=1-298.
2J9M X-ray 2.5Å A=1-298.
2JGZ X-ray 2.9Å A=1-288.
2R3F X-ray 1.5Å A=1-298.
2R3G X-ray 1.5Å A=1-298.
2R3H X-ray 1.5Å A=1-298.
2R3I X-ray 1.2Å A=1-298.
2R3J X-ray 1.6Å A=1-298.
2R3K X-ray 1.7Å A=1-298.
2R3L X-ray 1.6Å A=1-298.
2R3M X-ray 1.7Å A=1-298.
2R3N X-ray 1.6Å A=1-298.
2R3O X-ray 1.8Å A=1-298.
2R3P X-ray 1.6Å A=1-298.
2R3Q X-ray 1.3Å A=1-298.
2R3R X-ray 1.4Å A=1-298.
2R64 X-ray 2.3Å A=1-298.
2UUE X-ray 2.0Å A/C=1-298.
2UZB X-ray 2.7Å A/C=1-298.
2UZD X-ray 2.7Å A/C=1-298.
2UZE X-ray 2.4Å A/C=1-298.
2UZL X-ray 2.4Å A/C=1-298.
2UZN X-ray 2.3Å A=1-298.
2UZO X-ray 2.3Å A=1-298.
2V0D X-ray 2.2Å A=1-298.
2V22 X-ray 2.6Å A/C=1-298.
2VTA X-ray 2.0Å A=1-298.
2VTH X-ray 1.9Å A=1-298.
2VTI X-ray 2.0Å A=1-298.
2VTJ X-ray 2.2Å A=1-298.
2VTL X-ray 2.0Å A=1-298.
2VTM X-ray 2.2Å A=1-298.
2VTN X-ray 2.2Å A=1-298.
2VTO X-ray 2.1Å A=1-298.
2VTP X-ray 2.1Å A=1-298.
2VTQ X-ray 1.9Å A=1-298.
2VTR X-ray 1.9Å A=1-298.
2VTS X-ray 1.9Å A=1-298.
2VTT X-ray 1.6Å A=1-298.
2VU3 X-ray 1.8Å A=1-298.
2VV9 X-ray 1.9Å A=1-298.
2W05 X-ray 1.9Å A=1-298.
2W06 X-ray 2.0Å A=1-298.
2W17 X-ray 2.1Å A=1-298.
2W1H X-ray 2.1Å A=1-298.
2WEV X-ray 2.3Å A/C=1-298.
2WFY X-ray 2.5Å A/C=1-298.
2WHB X-ray 2.9Å A/C=1-298.
2WIH X-ray 2.5Å A/C=1-298.
2WIP X-ray 2.8Å A/C=1-298.
2WMA X-ray 2.8Å A/C=1-298.
2WMB X-ray 2.6Å A/C=1-298.
2WPA X-ray 2.5Å A/C=1-298.
2WXV X-ray 2.6Å A/C=1-298.
2X1N X-ray 2.7Å A/C=1-298.
2XMY X-ray 1.9Å A=1-298.
2XNB X-ray 1.8Å A=1-298.
3BHT X-ray 2.0Å A/C=1-298.
3BHU X-ray 2.3Å A/C=1-298.
3BHV X-ray 2.1Å A/C=1-298.
3DDP X-ray 2.7Å A/C=1-298.
3DDQ X-ray 1.8Å A/C=1-298.
3DOG X-ray 2.7Å A/C=1-298.
3EID X-ray 3.1Å A/C=1-298.
3EJ1 X-ray 3.2Å A/C=1-298.
3EOC X-ray 3.2Å A/C=1-298.
3EZR X-ray 1.9Å A=1-298.
3EZV X-ray 1.9Å A=1-298.
3F5X X-ray 2.4Å A/C=1-298.
3FZ1 X-ray 1.9Å A=1-298.
3IG7 X-ray 1.8Å A=1-298.
3IGG X-ray 1.8Å A=1-298.
3LE6 X-ray 2.0Å A=1-298.
3LFN X-ray 2.2Å A=1-298.
3LFQ X-ray 2.0Å A=1-298.
3LFS X-ray 2.4Å A=1-298.
3MY5 X-ray 2.1Å A/C=1-298.
3NS9 X-ray 1.7Å A=1-298.
3PJ8 X-ray 1.9Å A=1-298.
3PXF X-ray 1.8Å A=1-298.
3PXQ X-ray 1.9Å A=1-298.
3PXR X-ray 2.0Å A=1-298.
3PXY X-ray 1.8Å A=1-298.
3PXZ X-ray 1.7Å A=1-298.
3PY0 X-ray 1.7Å A=1-298.
3PY1 X-ray 2.0Å A=1-298.
3QHR X-ray 2.1Å A/C=1-296.
3QHW X-ray 1.9Å A/C=1-296.
3QL8 X-ray 1.9Å A=1-298.
3QQF X-ray 1.7Å A=1-298.
3QQG X-ray 1.9Å A=1-298.
3QQH X-ray 1.8Å A=1-298.
3QQJ X-ray 1.7Å A=1-298.
3QQK X-ray 1.8Å A=1-298.
3QQL X-ray 1.8Å A=1-298.
3QRT X-ray 1.7Å A=1-298.
3QRU X-ray 1.9Å A=1-298.
3QTQ X-ray 1.8Å A=1-298.
3QTR X-ray 1.8Å A=1-298.
3QTS X-ray 1.9Å A=1-298.
3QTU X-ray 1.8Å A=1-298.
3QTW X-ray 1.8Å A=1-298.
3QTX X-ray 1.9Å A=1-298.
3QTZ X-ray 2.0Å A=1-298.
3QU0 X-ray 1.9Å A=1-298.
3QWJ X-ray 1.7Å A=1-298.
3QWK X-ray 1.8Å A=1-298.
3QX2 X-ray 1.7Å A=1-298.
3QX4 X-ray 1.9Å A=1-298.
3QXO X-ray 1.7Å A=1-298.
3QXP X-ray 1.7Å A=1-298.
3QZF X-ray 2.0Å A=1-298.
3QZG X-ray 1.7Å A=1-298.
3QZH X-ray 1.9Å A=1-298.
3QZI X-ray 1.7Å A=1-298.
3R1Q X-ray 1.8Å A=1-298.
3R1S X-ray 1.8Å A=1-298.
3R1Y X-ray 1.8Å A=1-298.
3R28 X-ray 1.7Å A=1-298.
3R6X X-ray 1.7Å A=1-298.
3R71 X-ray 1.7Å A=1-298.
3R73 X-ray 1.7Å A=1-298.
3R7E X-ray 1.9Å A=1-298.
3R7I X-ray 1.8Å A=1-298.
3R7U X-ray 1.7Å A=1-298.
3R7V X-ray 1.9Å A=1-298.
3R7Y X-ray 1.9Å A=1-298.
3R83 X-ray 1.7Å A=1-298.
3R8L X-ray 1.9Å A=1-298.
3R8M X-ray 1.8Å A=1-298.
3R8P X-ray 1.8Å A=1-298.
3R8U X-ray 2.0Å A=1-298.
3R8V X-ray 1.9Å A=1-298.
3R8Z X-ray 1.8Å A=1-298.
3R9D X-ray 1.9Å A=1-298.
3R9H X-ray 2.1Å A=1-298.
3R9N X-ray 1.7Å A=1-298.
3R9O X-ray 1.9Å A=1-298.
3RAH X-ray 1.7Å A=1-298.
3RAI X-ray 1.7Å A=1-298.
3RAK X-ray 1.7Å A=1-298.
3RAL X-ray 1.7Å A=1-298.
3RJC X-ray 1.8Å A=1-298.
3RK5 X-ray 2.0Å A=1-298.
3RK7 X-ray 1.8Å A=1-298.
3RK9 X-ray 1.8Å A=1-298.
3RKB X-ray 2.0Å A=1-298.
3RM6 X-ray 1.6Å A=1-298.
3RM7 X-ray 1.8Å A=1-298.
3RMF X-ray 1.7Å A=1-298.
3RNI X-ray 1.9Å A=1-298.
3ROY X-ray 1.7Å A=1-298.
3RPO X-ray 1.7Å A=1-298.
3RPR X-ray 1.7Å A=1-298.
3RPV X-ray 1.8Å A=1-298.
3RPY X-ray 1.9Å A=1-298.
3RZB X-ray 1.9Å A=1-298.
3S00 X-ray 1.8Å A=1-298.
3S0O X-ray 2.0Å A=1-298.
3S1H X-ray 1.7Å A=1-298.
3S2P X-ray 2.3Å A=1-298.
3SQQ X-ray 1.8Å A=1-298.
3SW4 X-ray 1.7Å A=1-298.
3SW7 X-ray 1.8Å A=1-298.
3TI1 X-ray 1.9Å A=1-298.
3TIY X-ray 1.8Å A=1-298.
3TIZ X-ray 2.0Å A=1-298.
3TNW X-ray 2.0Å A/C=1-298.
3ULI X-ray 2.0Å A=1-298.
3UNJ X-ray 1.9Å A=1-298.
3UNK X-ray 2.1Å A=1-298.
3WBL X-ray 2.0Å A=1-298.
4ACM X-ray 1.6Å A=1-298.
4BCK X-ray 2.0Å A/C=1-298.
4BCM X-ray 2.4Å A/C=1-298.
4BCN X-ray 2.1Å A/C=1-298.
4BCO X-ray 2.0Å A/C=1-298.
4BCP X-ray 2.2Å A/C=1-298.
4BCQ X-ray 2.4Å A/C=1-298.
4BGH X-ray 1.9Å A=1-298.
4BZD X-ray 1.8Å A=1-298.
4CFM X-ray 2.8Å A/C=1-298.
4CFN X-ray 2.2Å A/C=1-298.
4CFU X-ray 2.2Å A/C=1-298.
4CFV X-ray 2.0Å A/C=1-298.
4CFW X-ray 2.4Å A/C=1-298.
4CFX X-ray 3.5Å A/C=1-298.
4D1X X-ray 2.1Å A=1-298.
4D1Z X-ray 1.8Å A=1-298.
4EK3 X-ray 1.3Å A=1-298.
4EK4 X-ray 1.2Å A=1-298.
4EK5 X-ray 1.6Å A=1-298.
4EK6 X-ray 1.5Å A=1-298.
4EK8 X-ray 1.7Å A=1-298.
4EOI X-ray 2.0Å A/C=1-298.
4EOJ X-ray 1.6Å A/C=1-298.
4EOK X-ray 2.5Å A/C=1-297.
4EOL X-ray 2.4Å A/C=1-297.
4EOM X-ray 2.1Å A/C=1-297.
4EON X-ray 2.4Å A/C=1-298.
4EOO X-ray 2.1Å A/C=1-297.
4EOP X-ray 1.9Å A/C=1-297.
4EOQ X-ray 2.1Å A/C=1-297.
4EOR X-ray 2.2Å A/C=1-297.
4EOS X-ray 2.5Å A/C=1-297.
4ERW X-ray 2.0Å A=1-298.
4EZ3 X-ray 2.0Å A=1-298.
4EZ7 X-ray 2.4Å A=1-298.
4FKG X-ray 1.5Å A=1-298.
4FKI X-ray 1.6Å A=1-298.
4FKJ X-ray 1.6Å A=1-298.
4FKL X-ray 1.2Å A=1-298.
4FKO X-ray 1.5Å A=1-298.
4FKP X-ray 1.6Å A=1-298.
4FKQ X-ray 1.7Å A=1-298.
4FKR X-ray 1.9Å A=1-298.
4FKS X-ray 1.5Å A=1-298.
4FKT X-ray 1.6Å A=1-298.
4FKU X-ray 1.4Å A=1-298.
4FKV X-ray 1.7Å A=1-298.
4FKW X-ray 1.8Å A=1-298.
4FX3 X-ray 2.7Å A/C=1-298.
4GCJ X-ray 1.4Å A=1-298.
4I3Z X-ray 2.0Å A/C=1-296.
4II5 X-ray 2.1Å A/C=1-298.
4KD1 X-ray 1.7Å A=1-298.
4LYN X-ray 2.0Å A=1-298.
4NJ3 X-ray 1.8Å A=1-298.
4RJ3 X-ray 1.6Å A=1-298.
5A14 X-ray 2.0Å A=1-298.
5AND X-ray 2.3Å A=1-298.
5ANE X-ray 1.7Å A=1-298.
5ANG X-ray 1.9Å A=1-298.
5ANI X-ray 1.9Å A=1-298.
5ANJ X-ray 1.6Å A=1-298.
5ANK X-ray 1.9Å A=1-298.
5ANO X-ray 1.7Å A=1-298.
5CYI X-ray 2.0Å A/C=1-298.
5D1J X-ray 1.8Å A=1-298.
5FP5 X-ray 2.1Å A=1-298.
5FP6 X-ray 1.8Å A=1-298.
5IEV X-ray 2.0Å A=1-298.
5IEX X-ray 2.0Å A=1-298.
5IEY X-ray 1.6Å A=1-298.
5IF1 X-ray 2.6Å A/C=1-298.
5K4J X-ray 1.6Å A=1-298.
5L2W X-ray 2.8Å A=1-298.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa04068 FoxO signaling pathway - Homo sapiens (human)
hsa04110 Cell cycle - Homo sapiens (human)
hsa04114 Oocyte meiosis - Homo sapiens (human)
hsa04115 p53 signaling pathway - Homo sapiens (human)
hsa04151 PI3K-Akt signaling pathway - Homo sapiens (human)
hsa04914 Progesterone-mediated oocyte maturation - Homo sapiens (human)
hsa05161 Hepatitis B - Homo sapiens (human)
hsa05162 Measles - Homo sapiens (human)
hsa05168 Herpes simplex infection - Homo sapiens (human)
hsa05169 Epstein-Barr virus infection - Homo sapiens (human)
hsa05200 Pathways in cancer - Homo sapiens (human)
hsa05203 Viral carcinogenesis - Homo sapiens (human)
hsa05215 Prostate cancer - Homo sapiens (human)
hsa05222 Small cell lung cancer - Homo sapiens (human)